PT  - JOURNAL ARTICLE
AU  - Jeeban P. Das
AU  - Hebert A. Vargas
AU  - Soleen Ghafoor
AU  - Alvin C. Goh
AU  - Gary A. Ulaner
TI  - Clinical Utility of <sup>18</sup>F-FDG PET/CT for Staging and Treatment Planning in Urachal Adenocarcinoma
AID  - 10.2967/jnumed.120.251561
DP  - 2021 May 10
TA  - Journal of Nuclear Medicine
PG  - 643--647
VI  - 62
IP  - 5
4099  - http://jnm.snmjournals.org/content/62/5/643.short
4100  - http://jnm.snmjournals.org/content/62/5/643.full
SO  - J Nucl Med2021 May 10; 62
AB  - Our objective was to evaluate the impact of 18F-FDG PET CT on the management of urachal adenocarcinoma (UrC-ADC). Methods: A retrospective analysis of patients with UrC-ADC from 2001 to 2019 at Memorial Sloan Kettering was performed. Mayo stage before 18F-FDG PET/CT, rate of detection of the primary malignancy and metastases on 18F-FDG PET/CT, Mayo stage after 18F-FDG PET/CT, and change in patient management were determined. Results: Of 21 patients with UrC-ADC before 18F-FDG PET/CT, Mayo staging was I/II in 8, III in 3, and IV in 10. 18F-FDG PET/CT detected previously unidentified metastases in 8 (38%) of 21 patients, resulting in upstaging of disease in 3 (14%) patients and a change in treatment in 4 (19%) patients. Conclusion: 18F-FDG PET/CT has clinical utility in patients with UrC-ADC by identifying metastatic disease not appreciated on anatomic imaging, leading to changes in staging and patient management.